BioNTech SE (BNTX) Gains from Investment Securities (2018 - 2025)
BioNTech SE (BNTX) posted Gains from Investment Securities of -$931234.8 for Q4 2025, up 38.73% sequentially from -$1.5 million in Q3 2025, and down 771.46% YoY from $138688.7 in Q4 2024.
BioNTech SE (BNTX) Gains from Investment Securities (2018 - 2025) Analysis & Trends
BioNTech SE has reported Gains from Investment Securities for 8 years, with the latest figure at -$931234.8 in Q4 2025.
- Quarterly Gains from Investment Securities fell 771.46% year-over-year to -$931234.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.9 million (down 2605.1% YoY) and the FY2025 annual result came in at -$2.8 million, down 781.07% from the prior year.
- Gains from Investment Securities grew to -$931234.8 in Q4 2025 per BNTX's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $211.5 million in Q2 2021 and troughed at -$1.5 million in Q3 2025.
- A 5-year average of $12.1 million and a median of $155273.7 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2021 and 2025: Gains from Investment Securities jumped 29630710.57% in 2021, then sank 771.46% in 2025.
- Over 5 years, Gains from Investment Securities stood at $4.8 million in 2021, then plunged by 95.75% to $204049.5 in 2022, then grew by 5.46% to $215188.0 in 2023, then slumped by 149.66% to -$106859.5 in 2024, then plunged by 771.46% to -$931234.8 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$931234.8, -$1.5 million, and -$339587.9 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931,234.81 |
| Dec 31, 2025 | -931,234.81 |
| Sep 30, 2025 | -1.52 Mn |
| Sep 30, 2025 | -1.52 Mn |
| Jun 30, 2025 | -339,587.91 |
| Jun 30, 2025 | -339,587.91 |
| Mar 31, 2025 | -105,188.44 |
| Mar 31, 2025 | -105,188.44 |
| Dec 31, 2024 | -106,859.54 |
| Dec 31, 2024 | -106,859.54 |
| Jun 30, 2024 | -215,377.52 |
| Jun 30, 2024 | -215,377.52 |
| Dec 31, 2023 | 215,187.98 |
| Dec 31, 2023 | 215,187.98 |
| Sep 30, 2023 | 3.59 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | 108,892.44 |
| Jun 30, 2023 | 108,892.44 |
| Mar 31, 2023 | 214,668.36 |
| Mar 31, 2023 | 214,668.36 |